

Supplemental Table for:  
Medical Oncologists' Perspectives on how the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer  
Irene Yu et al.

**Supplemental Table S1: Survey Responders' Recommended Adjuvant Therapy Pre- and Post-IDEA Collaboration: CAPOX versus FOLFOX**

		Pre-IDEA Collaboration		Post-IDEA Collaboration		OR for CAPOX Selection (95% CI)	P value
		CAPOX	FOLFOX	CAPOX	FOLFOX		
Overall Responses		N=28 (19.3)	N=117 (80.7)	N=79 (54.5)	N=66 (45.5)	5.0 (3.0-8.5)	<0.01
Geography	U.S., Canada	9 (22.5)	31 (77.5)	22 (55.0)	18 (45.0)	4.2 (1.6-11.1)	<0.01
	Europe, Australia, New Zealand	7 (38.9)	11 (61.1)	16 (88.9)	2 (11.1)	12.6 (2.2-72.3)	<0.01
	South America	6 (7.8)	71 (92.2)	34 (44.2)	43 (55.8)	9.4 (3.6-24.1)	<0.01
	Asia	6 (60.0)	4 (40.0)	7 (70.0)	3 (30.0)	1.6 (0.2-10.0)	n/a
Gender	Male	16 (18.0)	73 (82.0)	44 (49.4)	45 (50.6)	4.5 (2.3-8.8)	<0.01
	Female	11 (20.8)	42 (79.2)	34 (64.2)	19 (35.8)	6.8 (2.9-16.3)	<0.01
	N/A	1 (33.3)	2 (66.7)	1 (33.3)	2 (66.7)	1.0 (0.0-30.0)	n/a
Practice Setting	Academic	15 (29.4)	36 (70.6)	30 (58.8)	21 (41.2)	3.4 (1.5-7.8)	<0.01
	Community	6 (14.0)	37 (86.0)	21 (48.8)	22 (51.2)	5.9 (2.1-16.8)	<0.01
	Both	7 (13.7)	44 (86.3)	28 (54.9)	23 (45.1)	7.7 (2.9-20.2)	<0.01
Duration of Practice	Less than 10 years	14 (23.0)	47 (77.0)	35 (57.4)	26 (42.6)	4.5 (2.1-9.9)	<0.01
	More than 10 years	14 (16.7)	70 (83.3)	44 (52.4)	40 (47.6)	5.5 (2.7-11.3)	<0.01